Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ: ALVO )

11.58 -0.17 (-1.45%)
Streaming Delayed Price Updated: 12:07 PM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 Next >
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ALVO, ALVOW INVESTOR NEWS: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALVOW
From The Rosen Law Firm, P.A.
Via Business Wire
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
From Alvotech
Via GlobeNewswire
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
From Alvotech
Via GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
From Alvotech
Via GlobeNewswire
Alvotech Provides Update on Corporate Sustainability Framework
From Alvotech
Via GlobeNewswire
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
From Alvotech
Via GlobeNewswire
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
From Alvotech
Via GlobeNewswire
Settlement of Alvotech Private Share Placement Completed
From Alvotech
Via GlobeNewswire
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
From Alvotech
Via GlobeNewswire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
From Alvotech
Via GlobeNewswire
Alvotech Completes $137 Million Private Share Placement
From Alvotech
Via GlobeNewswire
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
From Alvotech
Via GlobeNewswire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
From Alvotech
Via GlobeNewswire
Alvotech Completes $59.7 Million Private Placement
From Alvotech
Via GlobeNewswire
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
From Alvotech
Via GlobeNewswire
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
From Alvotech
Via GlobeNewswire
Alvotech Announces Changes to its Leadership Team
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.